PYROJAS INC

Biotech · Private

PyroTIMER CAR-T cells—engineered T cells that durably inhibit TGF-β isoforms to overcome immunosuppression in tumors

Grants
$1.7M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · PyroTIMER Technology: Enabling T-Cell Persistence in Immunosuppressive Tumor Microenvironments$748,337
Federal grantDepartment of Health and Human Services · Phase II · PyroTIMER Technology: Enabling T-Cell Persistence in Immunosuppressive Tumor Microenvironments$999,283
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1725Jaguar Gene Therapy——
1726FAUNA BIO INCORPORATED——
1727Zyversa Therapeutics, Inc.—$3.6M
1728PYROJAS INC——
1729Chicago Biosolutions, Inc.——
1730DEMERX, INC.—$290K
1731Design Therapeutics, Inc.—$171M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 2
  • Immunotherapy Compositions And Methods Of Useapplication
  • Immunotherapy Compositions And Methods Of Useapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.